Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants - Concepedia

Concepedia

Publication | Open Access

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

DOI Full Paper Access

239

Citations

29

References

2019

Year

Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage, Orlando Antelope, Nadeem A. Vellore, Hein Than, Anna Reister Schultz, Phillip M. Clair, Amber D. Bowler, Anthony D. Pomicter,

Allosteric Inhibitor AsciminibMedicineImmunologyPharmacotherapyPonatinib Suppresses EmergenceAnti-cancer AgentPharmacologyRestores EfficacyNovel TherapyDrug DiscoveryDrug Resistance

References

	Year	Citations

Page 1

Page 1